当前位置: X-MOL 学术J. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A phase I/II randomized, placebo-controlled trial of romidepsin in persons with HIV-1 on suppressive antiretroviral therapy to assess safety and activation of HIV-1 expression (A5315)
The Journal of Infectious Diseases ( IF 6.4 ) Pub Date : 2020-12-22 , DOI: 10.1093/infdis/jiaa777
Deborah K McMahon 1 , Lu Zheng 2 , Joshua C Cyktor 1 , Evgenia Aga 2 , Bernard J Macatangay 1 , Catherine Godfrey 3 , Michael Para 4 , Ronald T Mitsuyasu 5 , Joseph Hesselgesser 6 , Joan Dragavon 7 , Curtis Dobrowolski 8 , Jonathan Karn 8 , Edward P Acosta 9 , Rajesh T Gandhi 10 , John W Mellors 1
Affiliation  

Romidepsin (RMD) is a histone deacetylase inhibitor reported to reverse HIV-1 latency. We sought to identify doses of RMD that were safe and induced HIV-1 expression.

中文翻译:

罗米地辛在 HIV-1 感染者中进行的 I/II 期随机、安慰剂对照试验,用于抑制性抗逆转录病毒治疗,以评估 HIV-1 表达的安全性和激活性 (A5315)

罗米地辛 (RMD) 是一种组蛋白脱乙酰酶抑制剂,据报道可以逆转 HIV-1 潜伏期。我们试图确定安全且可诱导 HIV-1 表达的 RMD 剂量。
更新日期:2020-12-22
down
wechat
bug